High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
Tali Azenkot, Mina Nikanjam, Soham Mhatre et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II clinical trial evaluated the efficacy of high dose interleukin-2 (HD IL2) combined with nivolumab in patients with checkpoint inhibitor-refractory metastatic melanoma or renal cell carcinoma. Among five enrolled patients, the overall response rate was 20%, with a median progression-free survival of 1.4 months. The trial was terminated due to a treatment-related death.
Key findings
- Overall response rate was 20% in patients with PD-1-refractory advanced melanoma or RCC.
- Median progression-free survival was 1.4 months.
- One treatment-related death occurred, leading to trial termination.
- Patients had a median of 3 prior lines of systemic therapy.
Why it matters
The study highlights the challenges of treating patients with advanced melanoma or renal cell carcinoma who are resistant to checkpoint inhibitors. Understanding the potential and limitations of combination therapies is crucial for developing future treatment strategies.
What to keep in mind
The study had a small sample size of five patients and was terminated early due to toxicity.